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Subacute necrotising encephalomyopathy (Leigh syndrome) due to cytochrome c oxidase (COX) deficiency is often caused by mutations
in the SURF1 gene, encoding the Surf1 protein essential for COX assembly. We have investigated five patients with different SURF1
mutations resulting in the absence of Surf1 protein. All of them presented with severe and generalised COX defect. Immunoelectrophoretic
analysis of cultured fibroblasts revealed 85% decrease of the normal-size COX complexes and significant accumulation of incomplete COX
assemblies of 90–120 kDa. Spectrophotometric assay of COX activity showed a 70–90% decrease in lauryl maltoside (LM)-solubilised
fibroblasts. In contrast, oxygen consumption analysis in whole cells revealed only a 13–31% decrease of COX activity, which was
completely inhibited by detergent in patient cells but not in controls. In patient fibroblasts ADP-stimulated respiration was 50% decreased
and cytofluorometry showed a significant decrease of mitochondrial membrane potential DWm in state 4, as well as a 2.4-fold higher
sensitivity of DWm to uncoupler. We conclude that the absence of the Surf1 protein leads to the formation of incomplete COX complexes,
which in situ maintain rather high electron-transport activity, while their H+-pumping is impaired. Enzyme inactivation by the detergent in
patient cells indicates instability of incomplete COX assemblies.
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1. Introduction isolated cytochrome c oxidase (COX) deficiency (LSCOX) isThe Leigh syndrome (LS) is a subacute necrotising
encephalopathy characterised by bilaterally symmetrical
necrotic lesions in subcortical brain regions with onset early
in infancy [1]. Heterogeneous genetic defects of both
mitochondrial and nuclear origin have been described as a
cause of LS [2]. The autosomal recessive LS associated with0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0925-4439(03)00127-3
Abbreviations: CS, citrate synthase; COX, cytochrome c oxidase;
GCCR, glycerophosphate cytochrome c reductase; SCCR, succinate
cytochrome c reductase; LS, Leigh syndrome; LSCOX, LS associated with
isolated cytochrome c oxidase deficiency; LM, lauryl maltoside; DWm,
mitochondrial membrane potential; TMRM, tetramethylrhodamine methyl
ester
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E-mail address: houstek@biomed.cas.cz (J. Housˇteˇk).the most common form of COX disorders [3] and one of the
most frequently occurring respiratory chain defects in in-
fancy and childhood. It was genetically confirmed that
LSCOX is caused by a nuclear gene disorder [4,5]. Further-
more, many of the cases studied belonged to a single
complementation group [6,7], suggesting one major locus
to be responsible for the disease.
Human COX is composed of 13 subunits: mtDNA genes
encode the 3 subunits forming the catalytic core of the
enzyme; the other 10 subunits are encoded by the nuclear
genome [8]. In addition, numerous nucleus encoded factors
are required for efficient assembly and maintenance of the
COX holoenzymes that are similar in yeast and human
[9,10]. Using different experimental techniques, two groups
identified mutations in SURF1 gene to be responsible for
LSCOX [11,12]. SURF1 encodes a protein homologous to
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COX [13].
The domain structure of this 30-kDa inner mitochondrial
membrane protein is well conserved among eukaryotes and
also prokaryotes which underlines its necessity for the
function of the respiratory chain [14]. To date, about 30
different pathogenic mutations in SURF1 have been de-
scribed [15]. Most of them are nonsense mutations inducing
the formation of a premature stop codon; missense and
splicing-site mutations are less common. It has been pro-
posed that the severe isolated COX defects result from
impaired assembly of the complex, which stops at the S2
intermediate before insertion of subunits II and III into the
heterodimer of subunits I and IV [16–18]. The decreased
steady-state level of COX subunits [19], pointing to a lesser
amount of the COX holoenzyme, is consistent with severely
decreased COX activity measured spectrophotometrically
[11]. Recent studies on calcium homeostasis in fibroblasts
of LSCOX patients suggest a decreased mitochondrial mem-
brane potential [20], which might be an important factor
negatively affecting the ATP synthesis ability, leading to
severe pathological phenotype of the disease. Another
analysis revealed increased thermosensitivity and greater
susceptibility to detergent inactivation of the COX from
LSCOX fibroblasts [21], resulting probably from the de-
creased stability of partially or improperly assembled
COX complexes. However, neither the exact role of SURF1
in COX assembly nor detailed characterisation of the
functional consequences of the defect has been reported.
In this paper we analysed fibroblasts from five LSCOX
patients with SURF1 mutation combining several experi-
mental techniques novel to LSCOX study. Our aim was to
gain further insight into the functional consequences of
SURF1 mutations on cell energetics.2. Materials and methods
2.1. Ethics
This study was carried out in accordance with the
Declaration of Helsinki of the World Medical Association
and was approved by the Committees of Medical Ethics at
all collaborating institutions. Informed consent was obtained
from parents.
2.2. Patients
All five children were born in term after an uncompli-
cated pregnancy with birth weight 3180–3500 g and length
49–52 cm. Their parents and siblings are healthy. In all
children, the postnatal adaptation and early psychomotor
development were normal in the first months of life, but
failure to thrive, progressive muscle hypotonia, hypertricho-
sis and severe delay in developmental milestones with
strabismus (patient 2 and 4), nystagmus (patient 3) oramaurosis (patient 1) were observed at the end of the first
year of life, followed by a total arrest of psychomotor
development. Biochemical analyses revealed hyperlactaci-
demia (blood-lactate 2.1–4.9 mmol/l; controls < 2.1) with
elevated lactate/pyruvate ratio (20–50; controls 10–18) and
increased lactate in cerebrospinal fluid (CSF-lactate 3.7–5.8
mmol/l; controls < 2.3). The MRI of the brain (in one case
CT) demonstrated symmetrical necrotic lesions in basal
ganglia corresponding to LS in all affected children. Four
children died after repeated respiratory infection due to
cardio-respiratory failure at the age between 3 and 5 years;
only one 11-year-old girl with prolonged course of the
disease (patient 3) is alive.
2.3. Cell cultures, mitochondria
Human skin fibroblasts were cultured in Dulbecco’s
modified Eagle’s medium (Sevac, Czech Republic) with
10% foetal calf serum (Sigma, Czech Republic). Cells were
grown to approximately 90% confluence and harvested using
0.05% trypsin and 0.02% EDTA. Detached cells were diluted
with ice-cold culture medium, sedimented by centrifugation
and washed twice in phosphate-buffered saline (PBS).
Mitochondria-enriched fractions (mitochondria) were
prepared from fibroblasts as before [22]. In brief, trypsinised
cells resuspended in 0.25 M sucrose, 10 mM Tris, 1 mM
EDTA, pH 7.4 (STE medium) were treated for 15 min with
digitonin (0.4 mg/mg protein; Fluka, Switzerland) at 0 jC.
The suspension was 10-fold diluted with STE and centri-
fuged at 12,000 g for 10 min. The pellet was resuspended
in STE, washed by centrifugation and resuspended to a final
concentration of 1–2 mg protein/ml. Based on immunode-
tection and enzyme activity measurements, more than 95%
of the inner mitochondria membrane proteins were recov-
ered in this fraction.
2.4. DNA analysis and sequencing
All nine exons of SURF1 were amplified using high-
fidelity KlenTaq polymerase (Gene Age Technologies,
Prague) in five separate PCR reactions with the intronic
primer pairs as described in Table 1. PCR products were
extracted from the gel and purified using QIAquick Gel
Extraction Kit (Qiagen). PCR products containing exons 1
and 2, very rich in GC, were amplified in the presence of
7-deazadGTP and dGTP (3:1), as described by Zhu et al.
[11]. Automated cycle sequencing was performed on Alf
express (Amersham Pharmacia Biotech) using AmpliTaq
polymerase (Applied Biosystems) and cy5-labeled sequenc-
ing primers.
2.5. Bacterial expression and purification of human Surf1
protein
A human SURF1 cDNA fragment (amino acids 51 to 300
of human Surf1) lacking its natural stop codon and its
Table 1
Primers for PCR amplification of exons 1 to 9 of SURF1
Exon(s) Oligonucleotide sequencesa Fragment size (bp) PCR cycle
1 and 2 sense: 5V-taatacgactcactatagggGCCCGGCAACTCGCTCATGG-3V 501 94 jC, 10 s; 68 jC, 30 s; 72 jC, 1 min
antisense: 5V-caggaaacagctatgacCGCTCAGCCGGCAGTTGGTTCAT-3V
3 and 4 sense: 5V-taatacgactcactatagggGCTCTAGGCAGCAGGTTTTGATT-3V 556 94 jC, 10 s; 62 jC, 30 s; 72 jC, 1 min
antisense: 5V-caggaaacagctatgacGGCAGTGACTAAAAGTCCCACCA-3V
5 sense: 5V-taatacgactcactatagggCCCTTTGCCTTTCTCCTTCACTT-3V 442 94 jC, 10 s; 62 jC, 30 s; 72 jC, 1 min
antisense: 5V-caggaaacagctatgacTCCTACCAAGGTTGGGGATTGT-3V
6 and 7 sense: 5V-taatacgactcactatagggCCTATGGGTGCCTGAGTGAC-3V 508 94 jC, 10 s; 62 jC, 30 s; 72 jC, 1 min
antisense: 5V-caggaaacagctatgacGAGGGTTAGGAGGAAGGACAGTA-3V
8 and 9 sense: 5V-taatacgactcactatagggAAGGCCATACAGGACTTCCAAC-3V 526 94 jC, 10 s; 62 jC, 30 s; 72 jC, 1 min
antisense: 5V-caggaaacagctatgacACTGAAACCAAGCCAGGATTTTA-3V
a SURF1 sequence is in capital letters, additional sequence complementary to the sequencing primers is in lowercase letters.
P. Pecina et al. / Biochimica et Biophysica Acta 1639 (2003) 53–63 55presumed mitochondrial signal sequence was inserted by TA
cloning into the plasmid pet-15B containing upstream to the
N-terminal Surf1p sequence a 6-His sequence and a throm-
bin site (to cleave the 6-His sequence). The plasmid was
used to transform bacteria JM109 (DE3) (Promega) made
competent by CaCl2 treatment. The protein was overex-
pressed in these bacteria by IPTG induction and purified on
an affinity nickel column following the QIA expressionistk
protocol and using 8 M urea, 10 mM sodium phosphate, 10
mM Tris and 0.25 M imidazole (pH 4.5) as elution buffer.
2.6. Electrophoretic and Western blot analysis
The samples for Blue-Native-polyacrylamide gel electro-
phoresis (BN-PAGE) were prepared as described [23].
Mitochondrial protein (150 Ag) derived from control and
patient fibroblasts was solubilised by digitonin (2 g/g
protein) in 50 mM NaCl, 5 mM 6-aminohexanoic acid, 50
mM imidazole/HCl buffer (pH 7.0) and centrifuged at
20,000 g for 20 min. The supernatants were collected
and the Serva Blue G dye was added in concentration of 0.1
g/g detergent. Protein aliquots (10 Ag) of these samples were
separated on a 6–18% gradient polyacrylamide slab gel
prepared according to Schagger [23] in Mini Protean system
(BioRad). The electrophoretic run was performed at 90 V
for 3.5 h.
The samples of fibroblasts and derived mitochondria for
SDS-PAGE were boiled for 3 min in a sample lysis buffer
(2% mercaptoethanol, 4% SDS, 10 mM Tris–HCl, 10%
glycerol). SDS-Tricine electrophoresis [24] was performed
on 10% or 12.5% polyacrylamide slab gels (Mini Protean,
BioRad). The same protein aliquots (10–15 Ag/slot) of
control and patient samples of mitochondria or original
fibroblasts (10) were loaded.
For immunodetection of Surf1 protein, proteins from
the gel were blotted onto a Schleicher and Schuellk
nitrocellulose membrane (0.2-Am pores) by semidry elec-
trotransfer at 0.7 mA/cm2 for 1 h. The membranes were
blocked with PBS containing 5% defatted milk and 0.1%
Tween 20, incubated with polyclonal anti-human Surf1
antibody (1:200 dilution, a generous gift from Dr. E.A.
Shoubridge, McGill University, Montreal, Canada) andthen with goat anti-rabbit IgG conjugated with horserad-
ish peroxidase (1:20,000, BioRad). The blots were de-
veloped using Super Signal West Femto substrate
(Pierce), essentially as described by Yao and Shoubridge
[19].
For immunodetection of respiratory chain enzymes,
proteins from the BN-PAGE or SDS-PAGE gels were
blotted onto Hybond C-extra nitrocellulose membrane
(Amersham) as above and the membrane was blocked in
PBS with 0.2% Tween 20 (PBST). The membranes from
BN-PAGE were used as a whole; the membranes from SDS-
PAGE were cut according to MW markers into parts
containing individual subunits. These parts were incubated
for 2.5 h with corresponding primary antibodies (monoclo-
nal antibodies against COX I (1:330), COX IV (1:670),
COX VIc (1:200) and F1-ATPase a subunit (1:250) from
Molecular Probes diluted in PBST containing 2% bovine
serum albumin (PBSTA), followed by incubation for 1.5
h with peroxidase labelled goat anti-mouse IgG (Sigma)
diluted 1:1000 in PBSTA. The chemiluminescent reaction
using ECL kit (Amersham) was detected on LAS 1000
(Fuji, Japan) and the signal was quantified using Aida 2.11
Image Analyser software.
2.7. Spectrophotometric measurements of respiratory chain
enzymes activities
COX, succinate-cytochrome c reductase (SCCR), glyc-
erophosphate-cytochrome c reductase (GCCR) and citrate
synthase (CS) were assayed at 30 jC as previously [25]. In
brief, samples of 0.1 mg protein of cultured cells were
solubilised with 4 mg lauryl maltoside (LM)/mg protein in 1
ml of 20 mM phosphate buffer at pH 7.4 and the COX
reaction was started by addition of 40 AM reduced cyto-
chrome c. SCCR and GCCR were measured in a medium
containing 10 mM potassium phosphate (pH 7.8), 2 mM
EDTA, 0.01% bovine serum albumin (fatty-acid-free), 0.2
mM ATP, 1 mM KCN, 5 AM rotenone and 10 mM succinate
or 20 mM glycerophosphate. Cells (0.2 mg protein) were
incubated with 1 mg digitonin/mg protein in 1 ml of the
medium for 2 min at 30 jC, then the reaction was started by
40 AM oxidised cytochrome c and assayed for 5 min. CS
Table 2
Mutations in SURF1 in five patients with Leigh syndrome due to COX
deficiency
Patient Exon Mutations Mutation type
P1 9/9 841 delCT/841
delCT
frameshift/frameshift: stop codon
870–872
P2 4/8–9 312 insATdel10/821
del18
frameshift: stop codon
316–318/exon 8 removal
P3 6/9 C574>T/841 delCT Arg192>Trp/frameshift: stop codon
870–872
P4 7/7 C688>T/C688>T Arg230>stop/Arg230>stop
P5 9/– 841 delCT/– frameshift: stop codon 870–872/–
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Tris–HCl (pH 8.2), 4 mg LM/mg protein, 0.1 mM dithioni-
trobenzoic acid and 0.2 mg protein of fibroblasts/ml. The
reaction was started with 5 AM acetyl CoA and changes of
absorbance at 412 nm were read for 1 min. This value was
subtracted from the rate obtained after subsequent addition
of 0.5 mM oxaloacetic acid.
2.8. Polarographic measurements
Oxygen consumption by fibroblasts was determined at 30
jC as described before [25] using the OROBOROS oxy-
graph (Innsbruck, Austria). Freshly harvested fibroblasts
were resuspended in a KCl medium (80 mM KCl, 10 mM
Tris–HCl, 3 mM MgCl2, 1 mM EDTA, 5 mM potassium
phosphate, pH 7.4) and cells (1 mg protein/ml) were per-
meabilised by digitonin using 0.05 mg/mg protein. Various
respiratory substrates and inhibitors were used as indicated.
Oxygen consumption was expressed in pmol oxygen/s/mg
protein. COX activity was measured with 5 mM ascorbate,
0.2 or 1 mM TMPD and 40 AM cytochrome c, and it was
corrected for autooxidation, which was determined as 0.33
mM KCN-insensitive oxygen uptake.
2.9. Cytofluorometric analysis of mitochondrial membrane
potential
Mitochondrial membrane potential (DWm) measurements
were performed on the FACSort flow cytometer (Becton
Dickinson, San Jose, CA, USA) according to Floryk and
Houstek [26]. Fibroblasts were resuspended in the KCl
medium containing 10 mM succinate at a protein concen-
tration of 1 mg/ml and permeabilised by 0.1 mg digitonin/
mg protein. Permeabilised fibroblasts were resuspended in
the KCl medium at 0.2 mg protein/ml and incubated with 20
nM tetramethylrhodamine methyl ester (TMRM, Molecular
Probes, USA). A minimum of 5000 cells was used for each
FACS measurement. Data were acquired on a log scale
using CellQuest (Becton Dickinson) and analysed with
WinMDI 2.8 software (Trotter, J., TSRI, La Jolla, USA).
Arithmetic mean values of fluorescence signal in arbitrary
units were determined for each sample for subsequent
graphic representation.
2.10. Protein determination
The protein content was measured according to the
method of Bradford [27] or by the Micro BCA protein
kit (BioRad), using bovine serum albumin as a standard.
Cell samples were sonicated for 20 s prior to protein
determination.
2.11. Statistics
Data are presented as meanF S.D. values derived from
parallel measurements in both patients and controls. Stan-dard t test or Mann–Whitney U test was used for signifi-
cance calculations (P < 0.05).3. Results
3.1. SURF1 mutations
DNA analysis revealed different mutations of SURF1
gene in the investigated patients (Table 2). Patient 1 was
homozygous for the frameshift mutation 841delCT that
introduces a premature stop codon in exon 9. This mutation,
first described by Tiranti et al. [28], has already been
reported for several other patients (for review see Ref.
[15]). Patient 2 exhibited mutation 312insAT/del10 which
occurs at high frequency in LSCOX patients and a 821del18
mutation which results in the removal of exon 8 [29].
Patient 3, who is the only one surviving at the age of 11
years, was heterozygous, carrying the 841delCT mutation
(see above) and a new C574T missense mutation in exon 6
that changed the arginine at position 192 to a tryptophan
[30]. Interestingly, the Arg192 is conserved in all eukaryots
but Arabidopsis thaliana while it is only occasionally found
in bacterial Surf1 homologs [14]. Patient 4 is homozygous
for the previously described mutation C688T changing the
arginine in position 230 into a stop codon [18,31]. Patient 5
carried the 841delCT mutation. No other mutation could be
detected in patient 5, similarly as in several other published
cases [32].
3.2. Absence of Surf1 protein
Fig. 1 shows that the Surf1 protein could not be detected
in fibroblast mitochondria of any of the five LSCOX patients
by Western blot analysis, using rabbit anti-human Surf1
antibody, although the antibody reacted well with isolated
Surf1 protein and clearly detected the Surf1 protein in
mitochondria from control fibroblasts.
3.3. Changes in COX activity and respiratory control
Fibroblasts from all LSCOX patients exhibited severely
decreased COX activity in comparison with control cells
Table 3
Spectrophotometric determination of enzyme activities in cultured
fibroblasts of LSCOX patients
Controls LSCOX patients Percent controls
COX 36.41F 9.73 7.43F 3.60 20.4*
SCCR 8.73F 1.80 8.57F 4.08 98.2
GCCR 7.83F 0.96 9.28F 2.77 118.6
CS 66.31F 35.72 63.94F 8.61 96.4
COX/CS 0.57F 0.25 0.14F 0.03 24.6*
Specific activities of cytochrome c oxidase (COX), succinate cytochrome c
reductase (SCCR), glycerophosphate cytochrome c reductase (GCCR) and
citrate synthase (CS) are expressed in nmol/min/mg protein. Values are the
meanF S.D. of measurements performed in 5 LSCOX and 5–30 control
fibroblast cultures.
*P< 0.01.
Fig. 1. Surf1 protein content in fibroblasts of patients with different SURF1
mutations. Surf1, 20 ng of recombinant Surf1 protein (amino acids 50 to
300, about 30 kDa); C, controls; P1–P5, patients 1 to 5. For analysis 15-Ag
protein of mitochondria from patient and control fibroblasts was used. The
arrow marks the position of Surf1 protein antigen.
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assay (Table 3). In the group of five patients the COX
was decreased approximately to 20% of the controls (the
mean values were 7.34 and 36.41 nmol cytochrome c
oxidised/min/mg protein in LSCOX patients and control
fibroblasts, respectively). We found similar decrease of
COX activity in all of our patients, despite the differences
in the course of the disease. Activities of other mitochon-
drial enzymes, SCCR, GCCR and CS, were the same as in
control cells. Thus, the COX activity related to CS, a
mitochondrial matrix marker, was fourfold decreased (0.14
in the LSCOX patients and 0.57 in the controls, respectively)
(Table 3).
By spectrophotometric analysis of COX using permea-
bilised mitochondria, a maximum activity is achieved
which is known to be in excess over the other components
of the respiratory chain; however, when the COX activity is
determined as oxygen consumption with TMPD+ ascorbate
in whole cells with intact mitochondria, the activity of
COX exceeds only by 1.5–2.5-fold the activity of respira-
tory chain dehydrogenases [33,34]. When we measured the
oxygen consumption by LSCOX fibroblasts in the presence
of FCCP, the activity of succinate oxidase accounted for
80% of the activity of controls (Fig. 2, Table 4). Similarly,
we found that COX activity in LSCOX fibroblasts with
SURF1 mutations was 69–87% of activity in control cells,
depending on the concentration of TMPD used. Thus, in
contrast to spectrophotometric measurements, the COX
activity in patient fibroblasts was much less decreased
when measured polarographically in cells containing intact
mitochondria.
Oxygraphic analysis further showed significantly lower
activation of respiration by ADP (Fig. 2), both absolutely
and in relation to state 3 uncoupled respiration. When using
succinate as a substrate, the ADP-stimulated respiration in
the patient cells was 50% decreased compared to control
fibroblasts (Table 4) and consequently, the ratio between
state 3-ADP and state 3-uncoupled respiration was 1.6-fold
lower in patient cells.
As shown in Fig. 3, the discrepancy between the spec-
trophotometric and polarographic detection of COX activity
in LSCOX fibroblasts resulted from a different sensitivity of
COX in LSCOX and control cells to detergent action.
Addition of 0.012% LM to the polarographic assay com-
pletely inhibited the COX activity in LSCOX fibroblasts butit was without any effect on the COX activity in control
cells. When we titrated the COX activity in LSCOX patients
by sequential additions of LM we found pronounced COX
inactivation already at about 0.009% of LM (Fig. 3). The
effect of LM was the same when using 0.2 mM TMPD (Fig.
3) or 1 mM TMPD (not shown). As solubilisation by LM is
routinely used in COX activity measurements in most
studies, it is highly probable that the very low COX activity
described in the literature in LSCOX patients reflects the
higher sensitivity of COX in LSCOX patients with SURF1
mutations to detergents.
3.4. The content and subunit composition of COX
complexes
To assess the amount and composition of COX complexes
in patient versus control mitochondria isolated from fibro-
blasts, we analysed digitonin-solubilised samples (2 mg/mg
protein) by the BN-PAGE and Western blotting using mono-
clonal antibody against subunit COX I (Molecular Probes
A6404) (Fig. 4A). Such analysis detects not only the COX
monomers but also supramolecular structures containing
COX [35] and assembly intermediates accumulating due to
alteration of assembly of the enzyme, because COX I is the
subunit starting the assembly process [16]. In LSCOX mito-
chondria compared to controls, the quantification revealed
only a 30% content of the total COX I signal and pronounced
changes of its distribution among several distinct structures.
Only half of the signal in LSCOX mitochondria comes from
COX assemblies found in control mitochondria, existing
either as COX monomers or COX-containing supramolecu-
lar structures with other respiratory chain enzymes. The
other half of the signal in LSCOX mitochondria was found
in assembly intermediates ranging in size from 90 to 120
kDa, which were absent in controls. Quantitatively, the COX
I in incomplete forms of patient COX made up about 15% of
the total COX I signal in controls.
In order to further characterize the respiratory chain
supramolecular structures according to Schagger’s nomen-
clature [35], we performed detection with antibody against
NADH39 subunit of complex I. Unlike to COX, the sum of
Fig. 2. Oxygen consumption by digitonin-permeabilised fibroblasts. Measurements were performed using 1.0 mg cell protein/ml and 0.05 mg digitonin/mg
protein. Subsequent additions of 10 mM succinate, 0.5 mM ADP, 1 AM oligomycin, 1 AM FCCP, 0.2 Ag/ml antimycin A (AA), 5 mM ascorbate, 0.2 mM
TMPD are indicated. Oxygen consumption is expressed as negative values of the 1st time derivative of changes in oxygen concentration (pmol O2/s/mg
protein).
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(Fig. 4A) and complexes III and V were also increased (data
not shown). In control mitochondria about 60% of COX and
virtually all complex I were associated in supracomplex bTable 4
Polarographic determination of succinate oxidase and COX activities in
fibroblasts of controls and LSCOX patients
Additions LSCOX patients Controls Percent
controls
10 mM succinate + 0.5 mM
ADP
64.25F 16.72
(n= 5)
129.34F 27.97
(n= 12)
50*
10 mM succinate + 1 AM
FCCP
142.61F 52.03
(n= 5)
179.31F 45.94
(n= 11)
80
5 mM ascorbate + 0.2 mM
TMPD+1 AM FCCP
52.14F 14.69
(n= 5)
65.83F 13.74
(n= 12)
87
5 mM ascorbate + 1 mM
TMPD+1 AM FCCP
191.39F 21.12
(n= 4)
275.84F 30.06
(n= 3)
69*
Activities are expressed in pmol oxygen/s/mg protein. Measurements of
oxygen consumption induced by ascorbate + TMPD represent KCN-
sensitive activities. Values are the meanF S.D.; n—number of experiments.
*P< 0.05.
Fig. 3. The effect of lauryl maltoside on COX activity in LSCOX and control
fibroblasts. COX activity measured polarographically with 5 mM ascorbate
and 0.2 mM TMPD is expressed in percent of the values obtained in the
absence of lauryl maltoside. Data are the meanF S.D. of measurements
performed in control (x, n= 7) and LSCOX (n, n= 5) fibroblasts.
Fig. 5. Cytofluorometric detection of mitochondrial DWm with TMRM.
Fibroblasts from control and LSCOX patients were permeabilised with
digitonin (0.1 mg/mg protein of cells) and stained with 20 nM TMRM in a
KCl medium containing 10 mM succinate. (A) Typical reading of TMRM
fluorescence in the presence and absence of 1 AM FCCP is shown. Intensity
of fluorescence (FL2 height) on the abscissa; cell number (events) on the
ordinate. (B) The meanF S.D. (n= 35–39) and statistical significance (*)
of data evaluated using the Mann–Whitney U test is shown.
Fig. 4. Electrophoretic analysis of COX in fibroblasts with SURF1
mutations. (A) BN-PAGE Western blot developed with anti COX I or anti
NADH39 monoclonal antibodies. Ten-microgram protein aliquots from
control (C) and patients 3 and 4 (P3 and P4) were loaded. Legend to marks:
i stands for incomplete COX assemblies, m stands for COX monomer, and
a, b, and c mark the respiratory supracomplexes I1III2, I1III2IV1, and
I1III2IV2, respectively. (B) SDS-PAGE Western blot of the COX subunits
content. Ten-microgram protein aliquots of mitochondria from control
fibroblasts (C) and from fibroblasts of LSCOX patients P1, P3, and P4 were
used for analysis. Detection was done with monoclonal antibodies to the a
subunit of F1-ATPase (F1 a) and COX subunits I, II, IV, and VIc. (C) The
graph shows the mean + S.D. values of the content of COX subunits
determined in three LSCOX patients, expressed in percent of controls.
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(I1III2IV2). The levels of both these structures were pro-
nouncedly decreased in samples from patients, where most
of the complex I was found in COX-lacking supracomplex a
(I1III2), most likely due to lack of complex IV needed for
stoichiometric assembly of greater structures.
To determine the composition of COX complexes in
LSCOX fibroblasts with SURF1 mutation, we performed
SDS-PAGE and Western blot analysis using commercially
available specific monoclonal antibodies against four dif-ferent COX subunits, COX I, COX II, COX IV, COX VIc,
and against subunit a of F1-ATPase (Molecular Probes,
antibodies A6403,lllkk A6404, A6409, A6401 and
A11144) (Fig. 4B). The detection with monoclonal anti-
bodies revealed about twofold decrease in the content of
COX I and COX IV subunits in mitochondria from LSCOX
patients (Fig. 4C). Even lower was the content of COX II
subunit (28% of the control) and the most reduced was the
content of COX VIc subunit (20% of the control). In
contrast, the content of the F1-ATPase a subunit was by
about 50% higher, this result together with the above BN-
PAGE data perhaps pointing to a compensatory mechanism
induced by impaired energy provision. The same results
were obtained when using whole fibroblasts (not shown).
These electrophoretic data indicate a substantial decrease
of the content of normal COX assemblies (monomer and
supracomplexes) in fibroblasts of our LSCOX patients.
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assemblies, some of which are lacking subunit II and/or
small nucleus-encoded subunits (represented by COX VIc
in our experiments), the assembly of which is dependent on
Surf1 protein action.
3.5. Changes in mitochondrial membrane potential
In order to evaluate the proton-pumping activity of the
respiratory chain in cells with SURF1 mutations, we ana-
lysed also the mitochondrial membrane potential (DWm) in
digitonin-permeabilised cells by cytofluorometry using cat-
ionic fluorescent dye—the TMRM. We found that under
steady-state conditions the LSCOX cells have significantly
decreased values of DWm at state 4. In comparison with
control fibroblasts, the LSCOX cells gave an 11% lower
value of TMRM fluorescence using succinate (Fig. 5) or
pyruvate and malate (not shown) as respiratory substrates,
and similar was the difference in membrane potential after
addition of the uncoupler FCCP (state 3 uncoupled), result-
ing in a 10% decrease of the FCCP-sensitive portion of
DWm (Fig. 5B). Furthermore, when we titrated the mem-
brane potential by low concentrations of FCCP, we found
much higher sensitivity to an uncoupler in fibroblasts with
SURF1 mutations. The FCCP titrations showed a 2.4-fold
increased sensitivity of LSCOX fibroblasts in comparison
with control cells (Fig. 6). I50 of FCCP was 12.5 and 30 nM
in patients and controls, respectively.
Partial uncoupling by FCCP leads to the dissipation of
proton gradient that must be compensated for by increasedFig. 6. Sensitivity of TMRM fluorescence to FCCP in fibroblasts from
controls and LSCOX patients. Digitonin-permeabilised (0.1 mg/mg protein)
fibroblasts were stained with 20 nM TMRM in the presence of 10 mM
succinate and various concentrations of FCCP (5–60 nM). TMRM
fluorescence is expressed as percentage of the mean fluorescence in the
absence of FCCP. Data are the meanF S.D. of measurements performed in
control (x, n= 3) and LSCOX (n, n= 5) fibroblasts. The arrows point to I50
concentrations of FCCP.proton-translocating activity of the respiratory chain
enzymes. The data presented in Fig. 6 thus indicate that
SURF1 mutation defects resulting in the modification of
structural properties of the COX holoenzyme are associated
with lower proton pumping activity and thus with impaired
maintenance of mitochondrial membrane potential needed
for sufficient ATP production.4. Discussion
COX represents the terminal enzyme complex of mito-
chondrial oxidative phosphorylation system and it is indic-
ative of the maximum capacity of the respiratory chain.
Recently, many reports showed that mutations of nuclear
genes encoding specific assembly proteins are responsible
for selective defects in biogenesis and assembling of COX
polypeptide subunits into the functional enzyme complex
[36–40]. Especially mutations of the SURF1 gene are often
responsible for a failure to assemble individual COX
subunits into a fully functional enzyme complex of the
inner mitochondrial membrane. It is also apparent that the
absence of Surf1 protein plays an important role in the
pathogenesis of LS, the most common clinical presentation
of COX deficiency in childhood. Defect of COX activity
appears to be the only mitochondrial abnormality in these
patients and it is expressed in all tissues including skin
fibroblasts.
Functional manifestation of SURF1 mutations is, how-
ever, still poorly understood. Despite the fact that the
activity of COX in various tissues of the patients is found
to be decreased to 1–20% of the controls, the onset of
clinical symptoms is delayed and during the first months of
life the patients present clinically normal (for review see
Ref. [41]). Also the assembly of COX is not completely
prevented and significant amount of normal COX com-
plexes is found in patients completely lacking the Surf1
protein [17].
The key finding of the present paper is that the electron-
transport activity of COX in fibroblasts of LSCOX patients
with different pathogenic SURF1 mutations is much less
affected in intact cells than indicated by the routine spectro-
photometric COX analyses. Despite this fact, we observed
impairment in ADP-stimulated respiration as well as in
proton pumping, manifested as decreased ability to maintain
normal values of mitochondrial membrane potential under
functional load. Using detailed electrophoretic analysis, we
found substantial changes in subunit composition of COX in
patient mitochondria. By opening a discussion on the
functional abilities of different forms of COX that we
detected, we try to provide explanation for our results of
activity measurements and present a simplified model of the
respiratory chain function in LSCOX patients (Fig. 7).
When we measured the activity of respiratory chain
enzymes in fibroblasts from LSCOX patients polarographi-
cally, we found only a small difference of COX and
Fig. 7. The schematic drawing of the hypothesised COX complexes present
in LSCOX patients. The complete COX enzyme present in 15% quantity
compared with control has normal electron-transport and proton-pumping
activity. The accumulated incomplete COX assemblies lacking small
nucleus-encoded subunits have up-regulated electron-transport activity, but
their proton-pumping ability is impaired.
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the COX activity of LSCOX cells was highly reduced in the
spectrophotometric measurement in the presence of a deter-
gent. This discrepancy between spectrophotometric and
polarographic data could be explained by different sensitiv-
ity of COX to the detergent in patient cells. In spectropho-
tometric measurement of COX, the mitochondrial
membrane has to be disrupted or solubilised to ensure
penetration of exogenous cytochrome c but when the
COX activity is measured as oxygen uptake, ascorbate
and TMPD are used as electron donors that freely react
with an endogenous cytochrome c in intact mitochondria.
We found that COX activity measured polarographically in
control fibroblasts is quite resistant to increasing concen-
trations of LM, whereas in fibroblasts with SURF1 mutation
the COX activity was highly decreased by the detergent
(Fig. 3). Importantly, we used the conditions (0.2–1 mM
TMPD+ 5 mM ascorbate), when the COX activity corre-
sponds well with oxidation of endogenous substrates in
intact cells or has only slight excess capacity, thus exhibiting
substantial control strength over the respiratory rate
[33,34,42]. Indeed, these recent experiments of Attardi’s
laboratory are in agreement with the concept of a ‘‘second
mechanism of respiratory control’’ postulated by Kadenbach
[43,44] that is based on regulation of COX activity and
H+/e ratios in vivo and contrast with the original studies
suggesting negligible control strength by COX (for review
see Ref. [45]). Similarly to our spectrophotometric assay,
usage of sonication instead of detergent also leads to
detection of only residual COX activity in patient cells
[46]. Increased sensitivity of COX to LM in the case of
LSCOX has been reported before [47]. While in control cells
they found a biphasic, activatory and inhibitory dependence
of COX activity, only the inhibitory phase was found in
LSCOX fibroblasts which contained reduced amount of
several nucleus-encoded subunits. Interestingly, the mono-
phasic COX dependence was also present in structurallysimple COX from Paracoccus denitrificans [48] which
lacks homologues of the most of mammalian subunits
encoded in the nucleus.
These data indicate that in accordance with delayed
manifestation of clinical symptoms, the metabolic conse-
quence of SURF1 mutation might be in fact milder than
generally expected from routine COX measurements. Po-
larographic oxygen consumption studies of respiratory
chain enzymes thus may better mirror the in vivo conditions
because the oxidative phosphorylation is fully functional,
while spectrophotometric analysis is advantageous in diag-
nostics of the COX defect due to unmasking of the lability
of the enzyme complex.
Based on significant decrease in ADP-stimulated respi-
ration and energy coupling in LSCOX fibroblasts, our char-
acterisation of the functional changes of COX due to SURF1
mutations was further aimed at the H+-translocating activity
of the respiratory chain. We used an indirect approach—the
cytofluorometric measurements of the mitochondrial mem-
brane potential DWm in permeabilised cells using TMRM as
fluorescent probe. In our previous studies this method
proved useful to detect the decrease in steady-state level
of DWm in fibroblasts and cybrids with a pronounced COX
defect due to A8344G MERRF mutation [49]. In the case of
LSCOX fibroblasts with various SURF1 mutations compared
with control cells, we found a small but significant decrease
in DWm at state 4 (Fig. 5) when the use of the proton
gradient is minimised. Furthermore, titrations with FCCP,
which simulate the functional load that must be compensat-
ed for by increased proton pumping from the matrix,
showed much higher sensitivity of patients’ fibroblasts to
the uncoupling effect of FCCP. This indicates a decrease of
proton pumping activity of COX in patient cells. Interest-
ingly, it has been suggested by Wasniewska et al. [20] on the
basis of calcium homeostasis studies that the LSCOX fibro-
blasts with SURF1 mutations may have a decreased DWm.
These functional changes should be related to changes in
the amount and composition of COX molecules in LSCOX
cells. Tiranti et al. [17] found that SURF1 mutation inter-
feres with assembly of COX subunits at the level of S2
subcomplex. They also detected only a small residual
portion of fully assembled enzyme complex, which agrees
very well with our results of 15% content of normal COX
assemblies in patient mitochondria. Interestingly, this esti-
mate corresponds well with the remaining COX activity in
LSCOX determined spectrophotometrically (Table 3). Based
on our BN-PAGE analysis, half of the total sum of COX
complexes in LSCOX exists as incomplete assemblies. It is
well established that LSCOX cells with SURF1 mutations
contain decreased amounts of various COX subunits, coded
for by mitochondrial and nuclear DNA, but the data differ in
various studies [19,31,50–53]. Our quantification in mito-
chondria from cultured fibroblasts showed an approximately
50% decrease of the content of subunits I and IV, a 70%
decrease of the subunit II and 80% decrease of the level of
VIc subunit, a pattern that was quite similar to the results of
P. Pecina et al. / Biochimica et Biophysica Acta 1639 (2003) 53–6362Yao and Shoubridge [19] or von Kleist-Retzow et al. [52].
The differential decrease of individual COX subunits in
patients with SURF1 mutations detected by us and in the
above-mentioned studies further indicates that incomplete
COX assemblies would preferentially lack some of the small
nucleus-encoded subunits. These findings, together with the
polarographic measurements of COX activity, showing that
half reduction of subunit I and IV and 70% reduction of
subunit II may still allow for a near-normal function of
respiratory chain-linked dehydrogenases in situ, are opening
the question to what extent and how the partially assembled
COX subcomplexes can operate. As hemes a and a3 are
present in COX subunit I, and assuming that also subcom-
plexes containing COX I +COX II are capable of electron
transfer activity, these incomplete COX assemblies must
contribute substantially to oxygen consumption determined
in polarographic experiments. This would be possible if
some of the incomplete, but functional, COX assemblies are
more active in electron transport but less in H+ pumping
activity than the complete COX complexes (Fig. 7). It has
been shown by Kadenbach’s group that the activity of COX
is increased upon removal or dissociation of subunit COX
VIb [54] or COX VIa [48], in accordance with the hypoth-
esis that small nucleus-encoded subunits physiologically
down-regulate the activity of the mammalian enzyme
[43,48].
It would be thus possible that the absence of some of the
nucleus-encoded subunits, as is generally found in SURF1
patients, may in fact paradoxically serve as some kind of a
rescue mechanism that keeps the COX electron transport
activity in situ only mildly decreased. This would provide
near-normal electron flux through the respiratory chain and
allow proton pumping at complexes I and III ensuring at
least decreased level of ATP synthesis.Acknowledgements
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